News
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...
With the agreement, the Foundation expands its existing collaboration with WHO, committing to a granting frame of up to DKK 380 million over the next four years.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are pitted against each other, but only one can be my preferred healthcare stock. Where to invest $1,000 right now? Our analyst team just revealed ...
Dividend growth and low payout ratios are key for long-term compounding. Click here for more information on Dividend ...
Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as its legal advisor. Evercore acted as the exclusive financial advisor ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...
European equity markets may thrive with monetary easing, fiscal expansion, and controlled inflation, despite risks from ...
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results